BMS plant closure "will halt vital HIV drug to children"
This article was originally published in Scrip
NGOs are concerned with plans by Bristol-Myers Squibb to close down its Meymac plant in France, saying it will affect supplies of the only prequalified second-line antiretroviral, Videx (buffered didanosine 25 mg tablets), for use in children with HIV in developing countries weighing less than 10kg.
You may also be interested in...
The US Food and Drug Administration recently signalled its desire to work more closely with other drug regulators in assessing the quality of pharmaceutical manufacturing facilities around the world.
It seems as if the US FDA is softening its stance on assessing the quality of pharmaceutical manufacturing facilities around the world in future, with an apparent desire to work more closely with other drug regulators. However, incorporating the regulators from countries such as India, China and Japan into a global inspectorate still looks problematical.
Large pharmaceutical companies and Médecins sans Frontières may not often see eye-to-eye over access to medicines in poor countries. But it seems as if industry and the humanitarian body, a prominent critic, do agree that competition works in improving access to vaccines, even though they don't agree about the mechanisms of price setting.